In recent years, there has been a significant improvement across the world in the quality of breast cancer treatment. However, many women continue to die from this life-threatening disease. This reality stresses the need for more improved early detection and still-better breast cancer therapies.
Breast cancer is a common cancer in women, and rarely occurs in men. Early-stage breast cancer can be treated with “breast conservation therapy,” involving limited removal of the tumor, sampling of the sentinel lymph nodes, and irradiation of the whole breast (with or without chemotherapy, depending upon other factors). Tomotherapy represents a significant advancement in medical equipment. It produces a very uniform radiation dose throughout the breast, minimizing “hot spots” which may be associated with bothersome skin reactions.
“Partial breast irradiation” appears to be as effective as whole-breast irradiation in lower-risk women, requiring only one week of treatment rather than the more-typical 6 weeks. More advanced or recurrent breast cancers may also be suitable for Tomotherapy, since treatment with its single continuous field avoids the “hot spots” that may result from adjacent fields overlapping — as may occur with conventional irradiation. Tomotherapy is also very efficient at minimizing the dose and damage to adjacent heart and lung tissues.
Under the able leadership and guidance of Dr. Grado, we have been able to devise appropriate medical plans that have been successful in reducing or eliminating the threats of breast cancer. Our trained radiation oncologists and nurses first evaluate the medical condition of the woman on a one-on-one basis, so that every medical detail is evaluated to devise a successful strategy for disease management. Our physicians strive to get the best possible treatment, according to the patient’s current medical state, involving one or more precise options that focus on eliminating the cancerous cells. We keep all our options open, and if required, refer our patients to specialists for suitable advice about surgery, radiation therapy, or the latest chemotherapy.
Our mission at Grado Clinics is to provide ideal treatment, along with a positive environment for the patient. With ongoing training at our state-of the-art facilities, we continue to plan targeted therapies that work in the best interests of our patients. The quality of our treatment and the amicable environment in our modern facilities have assisted us in achieving the distinction of being one of the top cancer treatment clinics.
1 Buwenge M, Cammelli S, Ammendolia I, et al. “Intensity modulated radiation therapy for breast cancer: current perspectives.” Breast Cancer Targets Ther. 2017;9:121–126.
2 Franco et al. “Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of TomoTherapy (TomoDirect): a prospective phase II trial.” J Cancer Res Clin Oncol. 2014 Jan;140(1):167-77. doi: 10.1007/s00432-013-1560-8.
3 Caudrelier et al. “IMRT sparing of normal tissues in locoregional treatment of breast cancer.” Radiat Oncol. 2014 Jul 22;9:161. doi: 10.1186/1748-717X-9-161.
4 Chitapanarux I, Nobnop W, Tippanya D et al. “Clinical outcomes and dosimetric study of hypofractionated Helical tomotherapy in breast cancer patients.” PLoS One. 2019 Jan 31;14(1):e0211578.
5 Arsene-Henry A, Foy JP, Robilliard M et al. “The use of helical tomotherapy in the treatment of early stage breast cancer: indications, tolerance, efficacy-a single center experience.” Oncotarget. 2018 May 4;9(34):23608-23619.
6 O’Donnell et al. “Early Experience of TomoTherapy-based Intensity-modulated Radiotherapy for Breast Cancer Treatment.” Clinical Oncology 2009 21: 294-301.
7 Van Prijs et al. “Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial.” Radiation Oncology 2012, 7:80.
8 Michalski et al. “A dosimetric comparison of 3D-CRT, IMRT and static tomotherapy with an SIB for large and small breast volumes.” Medical Dosimetry. 2014 Summer;39(2):163-8. doi: 10.1016/j.meddos.2013.12.003.